Ventyx Biosciences (VTYX) Competitors $3.56 -0.30 (-7.77%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$3.50 -0.06 (-1.80%) As of 10/10/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTYX vs. URGN, RZLT, ABUS, PHAT, KOD, VALN, XNCR, MNMD, SANA, and KURAShould you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include Urogen Pharma (URGN), Rezolute (RZLT), Arbutus Biopharma (ABUS), Phathom Pharmaceuticals (PHAT), Kodiak Sciences (KOD), Valneva (VALN), Xencor (XNCR), Mind Medicine (MindMed) (MNMD), Sana Biotechnology (SANA), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry. Ventyx Biosciences vs. Its Competitors Urogen Pharma Rezolute Arbutus Biopharma Phathom Pharmaceuticals Kodiak Sciences Valneva Xencor Mind Medicine (MindMed) Sana Biotechnology Kura Oncology Ventyx Biosciences (NASDAQ:VTYX) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation. Does the media favor VTYX or URGN? In the previous week, Urogen Pharma had 6 more articles in the media than Ventyx Biosciences. MarketBeat recorded 9 mentions for Urogen Pharma and 3 mentions for Ventyx Biosciences. Ventyx Biosciences' average media sentiment score of 0.87 beat Urogen Pharma's score of 0.69 indicating that Ventyx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ventyx Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, VTYX or URGN? Urogen Pharma has higher revenue and earnings than Ventyx Biosciences. Urogen Pharma is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVentyx BiosciencesN/AN/A-$135.12M-$1.68-2.12Urogen Pharma$90.40M8.54-$126.87M-$3.32-5.02 Which has more risk & volatility, VTYX or URGN? Ventyx Biosciences has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500. Do insiders and institutionals believe in VTYX or URGN? 97.9% of Ventyx Biosciences shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 14.5% of Ventyx Biosciences shares are held by insiders. Comparatively, 4.7% of Urogen Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate VTYX or URGN? Ventyx Biosciences presently has a consensus price target of $7.50, indicating a potential upside of 110.67%. Urogen Pharma has a consensus price target of $32.00, indicating a potential upside of 91.85%. Given Ventyx Biosciences' higher possible upside, equities analysts clearly believe Ventyx Biosciences is more favorable than Urogen Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ventyx Biosciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Urogen Pharma 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80 Is VTYX or URGN more profitable? Ventyx Biosciences has a net margin of 0.00% compared to Urogen Pharma's net margin of -164.44%. Ventyx Biosciences' return on equity of -48.89% beat Urogen Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Ventyx BiosciencesN/A -48.89% -44.87% Urogen Pharma -164.44%-97,487.15%-59.38% SummaryVentyx Biosciences beats Urogen Pharma on 10 of the 16 factors compared between the two stocks. Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTYX vs. The Competition Export to ExcelMetricVentyx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$275.25M$3.38B$6.10B$10.63BDividend YieldN/A2.29%5.67%4.71%P/E Ratio-2.1221.9785.2726.57Price / SalesN/A462.21612.78132.63Price / CashN/A47.2238.5062.09Price / Book0.9910.2112.726.53Net Income-$135.12M-$52.40M$3.30B$275.96M7 Day Performance-1.11%0.88%0.89%-0.77%1 Month Performance49.58%10.41%6.29%3.67%1 Year Performance66.36%27.28%80.41%37.30% Ventyx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTYXVentyx Biosciences2.0699 of 5 stars$3.56-7.8%$7.50+110.7%+73.7%$275.25MN/A-2.1230News CoverageAnalyst ForecastURGNUrogen Pharma3.8498 of 5 stars$19.14+4.4%$32.00+67.2%+40.1%$848.48M$90.40M-5.77200News CoverageAnalyst ForecastRZLTRezolute2.9161 of 5 stars$9.29-0.5%$14.50+56.1%+77.1%$848.18MN/A-9.5840Analyst ForecastABUSArbutus Biopharma1.7263 of 5 stars$4.46+1.1%$5.00+12.1%+8.4%$845.39M$6.17M-15.3890News CoverageNegative NewsAnalyst ForecastPHATPhathom Pharmaceuticals2.334 of 5 stars$11.33-3.8%$17.50+54.5%-24.8%$835.72M$55.25M-2.40110Analyst ForecastGap UpKODKodiak Sciences3.5625 of 5 stars$15.81+0.1%$13.00-17.8%+341.3%$834.58MN/A-4.1690News CoverageAnalyst ForecastAnalyst RevisionVALNValneva2.3005 of 5 stars$10.95+12.8%$15.00+37.0%+82.2%$834.35M$183.52M-11.17700Analyst ForecastGap UpXNCRXencor3.7358 of 5 stars$11.55-0.2%$22.25+92.6%-36.2%$825.21M$110.49M-4.81280News CoverageAnalyst UpgradeAnalyst RevisionGap UpMNMDMind Medicine (MindMed)2.2923 of 5 stars$12.04+12.8%$26.50+120.1%+128.4%$811.86MN/A-7.8740Analyst ForecastHigh Trading VolumeSANASana Biotechnology2.8537 of 5 stars$3.54+6.0%$7.50+111.9%+12.8%$794.27MN/A-3.34380News CoverageAnalyst ForecastKURAKura Oncology4.0649 of 5 stars$8.97-0.9%$24.10+168.7%-46.0%$785.52M$53.88M-3.97130Analyst Downgrade Related Companies and Tools Related Companies Urogen Pharma Competitors Rezolute Competitors Arbutus Biopharma Competitors Phathom Pharmaceuticals Competitors Kodiak Sciences Competitors Valneva Competitors Xencor Competitors Mind Medicine (MindMed) Competitors Sana Biotechnology Competitors Kura Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTYX) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
